Clinical trials: Prednisone, completed
Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-Cell Lymphoma
Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma
This study will be separated into 3 distinct phases designated as the Phase 1 study, Phase 2 pivotal study (Cohort 1 and Cohort 2), and Phase 2 safety management study (Cohort 3 and Cohort 4, Cohort 5 and Cohort 6).
- Conditions
- Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma (TFL), Primary Mediastinal B-cell Lymphoma (PMBCL)
- Trial name
- ZUMA-1 (NCT02348216)
- Testing
- Axicabtagene Ciloleucel, Fludarabine, Cyclophosphamide
- Where
- 36 sites in United States, Canada and 4 more
- Volunteers
- 307 people
- Sponsor
- Kite, A Gilead Company
Prostatic Neoplasms
Addition of Enzalutamide to First Line Docetaxel for Castration Resistant Prostate Cancer
The aim of this study is to verify if the addition of enzalutamide to docetaxel is able to improve the disease control in first line CRPC patients.
- Trial name
- CHEIRON (NCT02453009)
- Testing
- Docetaxel, Prednisone, Enzalutamide
- Where
- Italy
- Volunteers
- 246 people
- Sponsor
- Santa Chiara Hospital
Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma
Carfilzomib, Rituximab, and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Lymphoma
This phase I/II trial studies the side effects and best dose of carfilzomib when given together with rituximab and combination chemotherapy and to see how well they work in treating patients with diffuse large B-cell lymphoma.
- Conditions
- Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Stage I Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma
- Trial name
- NCT02073097
- Testing
- Carfilzomib, Rituximab, Cyclophosphamide
- Where
- 3 sites in United States
- Volunteers
- 48 people
- Sponsor
- Case Comprehensive Cancer Center
Asthma
A Serious Asthma Outcome Study With Mometasone Furoate/Formoterol Versus Mometasone Furoate in Asthmatics 12 Years and Over (P06241)
The purpose of this study is to test the safety of DULERA. DULERA is a pressurized metered-dose inhaler (MDI) that contains two drugs combined, namely mometasone and formoterol in a single inhaler.
- Trial name
- SPIRO (NCT01471340)
- Testing
- Mometasone Furoate/Formoterol MDI 100/5 mcg, Mometasone Furoate/Formoterol MDI 200/5 mcg, Mometasone Furoate MDI 100 mcg
- Volunteers
- 11,744 people
- Sponsor
- Organon and Co
Asthma
Study of Efficacy and Long-Term Safety of Mometasone Furoate in Combination With Formoterol Fumarate Versus Mometasone Furoate in Children (5 to 11 Years of Age) With Persistent Asthma (MK-0887A-087)
This study compares the 12-week efficacy and 24-week safety of mometasone furoate/formoterol fumarate (MF/F) 100/10 mcg and mometasone furate (MF) 100 mcg, both administered twice daily (BID) via metered-dose inhaler (MDI) in…
- Trial name
- NCT02741271
- Testing
- MF MDI 100 mcg BID (Open Label), MF/F MDI 100/10 mcg BID, MF MDI 100 mcg BID
- Volunteers
- 181 people
- Sponsor
- Organon and Co
Multiple Myeloma
A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)
The purpose of this study is to determine if the addition of daratumumab to VELCADE-melphalan-prednisone (VMP) will improve very good partial response (VGPR) or better compared with VMP alone.
- Trial name
- NCT03217812
- Testing
- Velcade, Melphalan, Prednisone
- Where
- 44 sites in China, Hong Kong and 3 more
- Volunteers
- 220 people
- Sponsor
- Janssen Research & Development, LLC
Advanced Follicular Lymphoma
An Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular Lymphoma
This open-label, single arm study will evaluate the safety of obinutuzumab administered as a short duration infusion (SDI; target 90-minute infusion) during cycle 2 and from cycle 2 onwards in combination with chemotherapy in…
- Trial name
- NCT03817853
- Testing
- Obinutuzumab, Bendamustine, Cyclophosphamide
- Where
- 33 sites in United States, Brazil and 5 more
- Volunteers
- 114 people
- Sponsor
- Hoffmann-La Roche
Uveitis
Methotrexate and Mycophenolate Mofetil for UVEITIS
In the First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial, the investigators propose to establish which immunosuppressive therapy, methotrexate or mycophenolate mofetil, is more effective as a…
- Trial name
- FAST (NCT01829295)
- Testing
- Mycophenolate mofetil, Methotrexate, Prednisone
- Where
- 9 sites in United States, Australia and 3 more
- Volunteers
- 216 people
- Sponsor
- University of California, San Francisco
B-cell Childhood Acute Lymphoblastic Leukemia, L1 Childhood Acute Lymphoblastic Leukemia
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
This randomized phase III trial is studying low-dose vincristine to see how well it works compared with high-dose vincristine when given together with different combination chemotherapy regimens in treating young patients with…
- Conditions
- B-cell Childhood Acute Lymphoblastic Leukemia, L1 Childhood Acute Lymphoblastic Leukemia, L2 Childhood Acute Lymphoblastic Leukemia, Intermediate Risk Recurrent Childhood Acute Lymphoblastic Leukemia
- Trial name
- NCT00381680
- Testing
- vincristine sulfate, prednisone, doxorubicin hydrochloride
- Where
- 173 sites in United States, Australia and 2 more
- Volunteers
- 275 people
- Sponsor
- Children's Oncology Group
Diffuse Large B-Cell Lymphoma Unclassifiable
Smart Start: A Phase II Study of Rituximab, Lenalidomide, and Ibrutinib
This phase II trial studies how well giving rituximab, lenalidomide, and ibrutinib with chemotherapy works in treating patients with high-risk diffuse large B-cell lymphoma.
- Trial name
- NCT02636322
- Testing
- Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- M.D. Anderson Cancer Center
Lymphoma
Clinical Trial to Evaluate R-COMP Versus R-CHOP in Newly Diagnosed Patients With Non-localised Diffuse Large B-cell Lymphoma (DLBCL)/Follicular Lymphoma Grade IIIb
The Phase II study proposed here assesses the hypothesis that replacing doxorubicin by Myocet® in the R-CHOP regimen would yield comparable antitumour efficacy with a lower cardiotoxicity for first-line treatment in elderly…
- Trial name
- NCT02012088
- Testing
- RCOMP, RCHOP
- Where
- 14 sites in Spain
- Volunteers
- 91 people
- Sponsor
- Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Bullous Pemphigoid
Observational Study Assessing Outcomes, Treatment Patterns and Related Costs in Patients in Bullous Pemphigoid
The study is an observational, multi-center, prospective, non-interventional and open-label data collection study assessing outcomes, treatment patterns, adverse events and costs in patients diagnosed with bullous pemphigoid.
- Trial name
- EDP-PB (NCT02837965)
- Testing
- treatment with topical superpotent corticosteroid therapy, treatment with systemic therapy (methotrexate), treatment systemic therapy (prednisone)
- Where
- France
- Volunteers
- 149 people
- Sponsor
- CHU de Reims
Uveitis
A Trial of the Efficacy and Safety of Izokibep in the Treatment of Non-anterior Uveitis
This is a multicenter, phase 2 trial to explore the efficacy and safety of Izokibep (ABY-035) in treating disease activity in patients with non-Infectious Intermediate, Posterior, Pan-Uveitis with significant disease activity at…
- Trial name
- LINNAEA (NCT04706741)
- Testing
- Izokibep, Prednisone/Prednisolone
- Where
- 4 sites in United States
- Volunteers
- 7 people
- Sponsor
- ACELYRIN Inc.
Prostate Cancer
Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)
The purpose of this study is to determine the clinical benefits of using a rapidly cycling, non-cross reactive regimen of FDA-approved prostate cancer therapeutic agents in the management of castration resistant prostate cancer.
- Trial name
- NCT02903160
- Testing
- Abiraterone acetate, Prednisone, Radium-223 dichloride
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Multiple Sclerosis
Safety and Tolerability of ISX (Isoxsuprine HCL) in MS Relapses
This is a proof of concept, randomized, double-blind, placebo-controlled, 2-arm, parallel group study of Isoxsuprine in MS subjects experiencing a typical relapse.
- Trial name
- NCT03752307
- Testing
- Isoxsuprine Hydrochloride, Corticosteroid
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of New Mexico
Tuberculous Lymphadenitis, Cervical
Steroids vs Placebo in Treatment of Tuberculous Lymphadenitis
This study will be conducted as a single blinded randomized control trial. The goal of this clinical trial is to learn about the role of low dose steroids in the resolution of tuberculous lymphadenitis.
- Trial name
- NCT06236152
- Testing
- Ferrous sulfate, Deltacortril
- Where
- Pakistan
- Volunteers
- 140 people
- Sponsor
- Fahad Javed Awan
Prostate Cancer
Anti-Androgens and Cabazitaxel in Defining Complete Response in Prostatectomy (ACDC Trial)
This study evaluates the use of chemotherapy with cabazitaxel in addition to abiraterone acetate, prednisone, and leuprolide in neoadjuvant setting prior to radical prostatectomy in patients with high-risk prostate carcinoma.
- Trial name
- ACDC-RP (NCT02543255)
- Testing
- Abiraterone acetate with prednisone, Leuprolide, Cabazitaxel with peg-filgrastim
- Where
- 5 sites in Canada
- Volunteers
- 76 people
- Sponsor
- University Health Network, Toronto
Nephrotic Syndrome
Prednisolone Trial in Children Younger Than 4 Years
This study is a multicentric, randomized, parallel group, open label controlled trial of children age 1 year up to 4 years with new onset, idiopathic nephrotic syndrome.
- Trial name
- NCT03141970
- Testing
- Prednisolone
- Where
- 5 sites in United States, India
- Volunteers
- 170 people
- Sponsor
- All India Institute of Medical Sciences
Multiple Myeloma
Subcutaneous Velcade Plus Oral Melphalan and Prednisone or Plus Cycloposphamide and Prednisone or Plus Prednisone
This protocol is a single-arm, three-cohort, phase II multicenter study designed to assess the safety and the efficacy of three all-oral combinations: Velcade with continuous low-dose melphalan and prednisone (VMP) or with…
- Trial name
- NCT01190787
- Testing
- velcade subcutaneous melphalan prednisone, velcade cyclophosphamide prednisone, velcade prednisone
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- European Myeloma Network B.V.
Relapsed or Refractory Multiple Myeloma
Selinexor, Cyclophosphamide and Prednisone in Myeloma
The trial is designed as a randomised, controlled, open, parallel group, multi-centre phase II trial to evaluate clinical efficacy of selinexor in combination with cyclophosphamide and prednisone.
- Trial name
- MUKtwelve (NCT06212596)
- Testing
- Selinexor, Cyclophosphamide, Prednisone
- Where
- 13 sites in United Kingdom
- Volunteers
- 66 people
- Sponsor
- University of Leeds